Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
PDC31 (formerly THG113.31)
print preview
bookmark
share with colleague
General Information
Company
Theratechnologies Inc.
Description
Injectable formulation of prostaglandin F2-alpha receptor antagonist
Molecular Target
Prostaglandin F (FP) receptor (PTGFR)
Mechanism of Action
Prostaglandin F (FP) receptor antagonist
Latest Stage of Development
Phase I
Indication
Uterine contractions
Partner
PDC Biotech GmbH
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy